HLA-expressing transgenic mice to identify tumor-specific TCRs for cancer treatment: Application to Hepatocarcinoma

Project information

Using transgenic mice expressing human MHC (HLA) molecules, our laboratory has identified TCRs specific to a tumor antigen present in different types of tumors, such as hepatocarcinoma (HCC), in the context of the HLA-A2 molecule.  Human T lymphocytes modified with these TCRs are able to recognize different HLA-A2+ HCC lines expressing this antigen, as well as to control the growth of human HCC tumors in xenograft models. Our next objective is to is to transfer these TCRs to the clinic.

• Reference: PI21/00292
• Start date: December 1, 2023
• End date: December 31, 2023
• Funder: Instituto de Salud Carlos III
• Nature of project: National